[MiNDERA Corp.]
329 Oyster Point Boulevard
MiNDERA Corp.
Non-invasive molecular testing for skin cancer
MiNDERA Corp. is developing an alternative to punch biopsies for diagnosing skin cancer: its microneedle device extracts biomarkers from the skin in a procedure that the start-up says is highly accurate and cost-effective for office-based diagnostic applications in dermatology.
More from Archive
More from Medtech Insight
• By
Fresh off an IPO, spinal implant maker Carlsmed is preparing to launch a new cervical fusion application for its aprevo tech. Medtech Insight has two perspectives on these recent moves: CEO Mike Cordonnier and the doctor who performed the first spinal fusion using the technology.
• By
Daye is launching an at-home reproductive hormone testing service in the UK, utilizing a painless upper arm blood collection method. The product’s UKAS lab accreditation helps build credibility with healthcare providers.
• By
BD raised its adjusted earnings per share guidance midpoint by $0.18 to a range of $14.30 to $14.45, representing growth of about 9.4% at the midpoint – an increase of approximately 1.4% over prior guidance.